# Academic Curriculum Vitae

## DON H. CATLIN, M.D.

**COMMUNICATIONS:**


| | |
|---|---|
| Telephone: | ADR 310-482-6925 (UCLA seldom 310-825-2635) |
| Facsimile: | ADR 310-482-6929 |
| Email: | dcatlin@antidoping research.org or dcatlin@ucla.edu |
| Address: | Anti-Doping Research<br>3873 Grand View Blvd.<br>Los Angeles, Ca. 90066<br>or<br>UCLA Olympic Analytical Laboratory<br>2122 Granville Avenue<br>Los Angeles, Ca. 90025 |


**PERSONAL HISTORY:**

| | |
|---|---|
| Address: | 12415 Rochedale Lane, Los Angeles, CA. 90049 |
| Date of Birth: | June 4, 1938 Connecticut |
| Marital status: | Widowed, 1989 |
| Children: | Bryce 1974, Oliver 1976 |

**EDUCATION and TRAINING:**

| | | |
|---|---|---|
| Yale University | B.A. | 1960 |
| University of Rochester<br>School of Medicine | M.D. | 1965 |
| University of California,<br>Los Angeles<br>Department of Medicine | I Internship<br>II Residency | 1965-1966<br>1966-1967 |
| University of Vermont<br>Department of Medicine | III Residency | 1967-1968 |

**EDUCATION and TRAINING: (continued)**

| | | |
|---|---|---|
| University of California, Los Angeles Department of Medicine | IV Residency Chief Resident | 1968-1969 |

**PRESENT POSITIONS: UNIVERSITY OF CALIFORNIA, LOS ANGELES**

| | |
|---|---|
| Professor of Molecular and Medical Pharmacology | 2002 - 2007 - |
| Professor Emeritus of Molecular and Medical Pharmacology | 2007 - |
| Founder and Director, UCLA Olympic Analytical Laboratory | 1982 - 2007 |

**PRESENT POSITIONS: LOCAL, NATIONAL AND INTERNATIONAL**

| | |
|---|---|
| Anti-Doping Research Institute (Not for Profit) | |
| President | 2006 |
| International Olympic Committee (IOC) | |
| Member, Medical Commission | 1989 - |
| Chair. Science and Medicine Committee | 2003 - |
| World Anti-Doping Agency (WADA) | |
| Laboratory Director | 2000 - 2007 |
| Member Medicine and Science Committee | 2007 - |
| Los Angeles Sheriffs Department, Medical Review Officer | 1991 - |

**CERTIFICATION:**

| | | |
|---|---|---|
| License to Practice Medicine: | California | 1965- |
| | Vermont | 1967 - 1990 |
| | District of Columbia | 1968 - 1980 |
| Diplomate: American Board of Internal Medicine | | 1970 |

**UCLA OLYMPIC ANALYTICAL LABORATORY CERTIFICATION:**

| | |
|---|---|
| The International Olympic Committee | 1983 - |
| College of American Pathologists | 1993-2001 |
| International Organization for Standardization (ISO) | 1999 - |

**UCLA OLYMPIC ANALYTICAL LABORATORY CERTIFICATION:** (continued)

U.S. Department of Defense 2000 -

World Anti-Doping Agency (WADA) 2004 -

**PAST ACADEMIC POSITIONS:**

University of California, Los Angeles

Department of Medicine
Assistant Professor 1972-1979
Associate Professor 1979-2001

Department of Pharmacology
Assistant Professor 1972-1979
Associate Professor 1979-2001

**PAST POSITIONS:**

United States Army Medical Corps 1969-1972

Walter Reed Army Institute of Research, Washington, D.C.,
Captain 1969-1970, Major (retired, 1972)
Department of Medicine, Gastroenterology

District of Columbia, Department of Health

Director, Substance Treatment Clinic 1971-1972

University Committees

Physicians Health Committee, UCLA Medical Center 1991 -

International Federation of Clinical Chemistry:

Committee on Laboratory Analysis of Drugs of Abuse, Chairman 1988-1996

International Olympic Committee

Subcommission on Out-of-Competition Testing. 1991-1999
Various working groups

**PAST POSITIONS (continued):**

United States Olympic Committee

Committee on Substance Abuse, Research and Education
Founding Chairman 1985-1989
Member 1989-2000

International Doping Control Working Group, U.S. representative. 1987-1999

Soviet-American Joint Drug Education & Anti-doping Commission 1988-1992

National Collegiate Athletic Association:

Various committees 1985-2001

Council of Europe, Invited Delegate: 1987-1994

**PROFESSIONAL ACTIVITIES: MEMBERSHIP**

The Androgen Society

California Medical Association

Western Society for Clinical Research

American Association for the Advancement of Science

American Chemical Society

International Federation of Clinical Chemistry

American Association for Clinical Chemistry

U.S. Pharmacopeial Convention

**PROFESSIONAL ACTIVITIES: CONSULTATION**

Editorial Service: Various scientific journals including: JAMA, Nature, Steroids, J Clinical Endocrinology and Metabolism, and J Mass Spectrometry

Editorial Board: The Georgia Tech Sports Medicine and Performance Newsletter
Drugs and sport reviewer for Clinical Chemistry

United States: U.S. Information Agency
Department of Defense

**PROFESSIONAL ACTIVITIES: CONSULTATION (continued)**

National Institute on Substance Abuse

Health and Human Services
Food and Drug Administration
Office of National Drug Control Policy
Drug Enforcement Agency
Department of Justice
Armed Forces Institute of Pathology

State of California: Department of Alcohol and Drug Programs, Health and Welfare Agency
Department of Health Services, Board of Medical Quality Assurance
California Horse Racing Board
State Compensation Insurance Fund, Department of Justice
Department of Education
Lawrence Livermore Laboratories

City of Los Angeles: Chief Medical Examiner-Coroner
City Attorney's Office
Los Angeles Police Commission

Sport Organizations: National Collegiate Athletic Association

United States Olympic Committee and all USOC National Sport Governing Bodies such as USA Track and Field

International Sport Federations, various and including: International Amateur Athletic Federation, Cycling (UCI), soccer (FIFA)

National Football League

National Strength and Conditioning Association

Various colleges and universities

Major Media Consultant on Drugs and Sport:

Examples: New York Times; Washington Post; Los Angeles Times; British Broadcasting Corporation; London Times; Sports Illustrated; ABC, CBS, and NBC Sports; Turner Sports; ESPN Sports; Time, and National Public Radio.

**HONORS AND SPECIAL AWARDS:**

Alpha Omega Alpha Honor Medical Society 1965

**HONORS AND SPECIAL AWARDS: (continued)**

International Olympic Committee:

Distinguished Sports Medicine Physician Award 1989

National Strength and Conditioning Association:

| | |
|---|---|
| Presidents Award | 1990 |

Los Angeles Times

| | |
|---|---|
| 100 Most Influential Persons in Sport | 1990 |

American Society of Mass Spectrometry

| | |
|---|---|
| Plenary Speaker | 1995 |
| Plenary Speaker | 2005 |

Sportsman of the Year, 2003

| | |
|---|---|
| Chicago Tribune | 2003 |

**INVITED LECTURES: INTERNATIONAL AND NATIONAL, since 1990**

Main Topics: 1. Clinical Uses of Anabolic Androgenic Steroids; 2. Adverse Effects of Anabolic Steroids; 3. Testing for Anabolic Steroids; 4. Antidoping Activities in the U.S.; 5. Carbon Isotope Ratio Techniques; 6) Pharmacology of Drugs of Abuse; 7) Tetrahydrogestrinone.

American Society of Addiction Medicine, Annual Meeting. Boston, MA November, 1990.

Council of Europe, U.S. delegate. Anti-doping Convention. Strasbourg, France. June, 1991.

National Collegiate Athletic Association (NCAA). Annual Conference for Physicians.
Sun Valley, Idaho. June 24, 1991.

U.S. Drug Enforcement Agency - Symposium on Anabolic steroids. Boston, MA. July 1991.

Surgeon General: U.S. Department of Defense. Fort Sam Houston, Texas. August, 1991.

Third Permanent World Conference on Drugs in Sport. Bergen, Norway. September, 1991.

American Society of Addiction Medicine. Cleveland, Ohio. April, 1991.

Keynote Speaker: Analytical Considerations in doping Control in Olympic and Sports Medicine.
Federation for Analytical Chemistry and Spectroscopy Society. Anaheim, CA. October, 1991.

**INVITED LECTURES: INTERNATIONAL AND NATIONAL, since 1990 (continued)**

United States Olympic Committee: Olympic Congress of the USA. Colorado Springs, Co. November, 1991.

Soviet Sportsmedicine in cooperation with Soviet-American Joint Commission on Drug Abuse. Moscow, Soviet Union December 1991.

Pittsburgh Conference. (GC-MS of Anabolic Steroids) New Orleans, LA. March, 1992.

National Football League. Washington, D.C. and Denver, CO. May, 1992.

Federal Bureau of Investigation. Toxicology Symposium. Quantico, VA. June, 1992.

Council of Europe, Anti-Doping Convention. Strasbourg, France. December, 1992.

Central American Caribbean Scientific Congress. San Juan, Puerto Rico. March, 1993.

Symposium: Control of Doping with Anabolic Steroids. London, U.K. September, 1993.

Fourth Permanent World Conference on Anti-doping in Sport. London, UK. September, 1993.

Centenial of the International Olympic Committee. Paris, France. August, 1994.

Royal Pharmaceutical Society of Great Britain. 131st British Pharmaceutical Conference. London, England. September, 1994.

Second International Androgen Workshop. Agency for International Development. Long Beach. February 1995.

XIIth Doping Control Seminar. Cologne, Germany March, 1995.

Plenary Speaker: American Society of Mass Spectrometry. Atlanta, Georgia. May, 1995.

Seminar, Hewlett Packard. Palo Alto, CA. May, 1995.

National Association of Athletic Trainers. Indianapolis, In. June, 1995.

University of Oregon. Ashland, Oregon August, 1995.

Australian Society of Mass Spectrometry. University of New South Wales, Sidney, Australia September, 1995.

World Congress of Sports Medicine. Atlanta, Georgia. September, 1995.

**INVITED LECTURES: INTERNATIONAL AND NATIONAL, since 1990 (continued)**

University of Rochester, October, 1995.

HPLC Annual Meeting, keynote speaker, May, 1996.

XVIth World Congress of Clinical Chemistry. London, UK. July, 1996.

American College of Sports Medicine, June, Orlando, June, 1998.

USOC Olympic Congress, Phoenix, Arizona. November, 1998.

Australian International Symposium on Analytical Science. Melbourne, Australia. July, 1999.

Australian Sports Medicine Association, Sydney, Australia. July, 1999.

American Medical Society for Sports Medicine, San Diego, March, 2000.

American College of Sports Medicine, Indianapolis, May, 2000.

The Endocrine Society, Toronto, Canada, June, 2000.

American Orthopedic Society for Sports Medicine, Los Angeles, March, 2002.

British Medical Association, London, UK, April, 2002.

American Association for the Advancement of Science (AAAS) Current Pharmacological Doping Methods and Banned Substances. Seattle, WA, February 2004.

International Association of Horseracing Chemists and Veterinarians, Dubai UAR March, 2004.

American Society of Andrology. Use, Abuse, and Addiction to Anabolic Steroids. Baltimore, MD, April 2004.

American College of Sports Medicine. Indianapolis, IN, June 2004.

The Endocrine Society - Science Writers Conference. New York, NY, December 2005.

Neutracon Supplement Meeting. February 2006

Annual Meeting of American Society of Clinical Pathologists, Las Vegas, Nevada, October 2006

World Boxing Council - Use, Abuse, and Addiction to Anabolic Steroids
World Boxing Council - Role of blood doping and erythropoietins in sport.
April, 2007 Cancun Mexico.

**INVITED LECTURES: UCLA AND CALIFORNIA, since 1990**

California State Department of Health Services: Public Health Grand Rounds. March, 1990.

UCLA Neuropsychiatric Institute: Substance Abuse Focus Group. UCLA. May, 1990.

Symposium: Sports Alcohol and Other Drugs. Oakland, CA. October, 1990.

Grand Rounds. Childrens Hospital, Oakland, CA. August, 1990.

Pacific Interurban Clinical Club. Los Angeles, CA. November 3, 1990.

Obstretrics and Gynecology Endocrinology Seminar. UCLA. January, 1991.

California Society of Addiction Medicine. San Francisco, CA. October, 1991.

Los Angeles Police Commission. Los Angeles, CA. March, 1992.

Saint John's Hospital and Health Center. Santa Monica, CA. September, 1992.

California Society of Addiction Medicine. Anaheim, CA. November, 1992.

Obstretrics and Gynecology Assembly of Southern California. Los Angeles, CA. February, 1993.

World Cup Soccer, Federation International Football Association. Los Angeles, CA. April 1994.

UCLA School of Medicine - Interdepartmental Conference. UCLA. May, 1994.

Grand Rounds, Hoag Memorial Hospital, September, 1995.

Harbor-UCLA Endrocrine Grand Rounds, October, 1995.

Wadsworth Veterans Administration, Endocrinology Grand Rounds, March, 1996.

Division of Family Practice, UCLA, October, 1996.

Harbor-UCLA Endocrine Grand Rounds, April, 1998.

UCLA School of Medicine, Grand Rounds, June, 2002.

Solvay Course on Androgens Manhatten Beach, April, 2003.

American Association for the Advancement of Science, Seattle, February, 2004.

UCLA Department of Pediatrics, Endocrinology, Grand Rounds, October, 2004.

**INVITED LECTURES: UCLA AND CALIFORNIA, since 1990 (continued)**

UCLA-Wadsworth, Department of Endocrinology, Grand Rounds, January, 2005.

**SEMINARS & SYMPOSIA ORGANIZED AND PRESENTED, since 1989**

Chairperson and Principal Speaker: CME Course on Drugs in Sport for Physicians associated with United States Olympic Committee.
UCLA Medical Center, Los Angeles, CA. May 1989.

Second Permanent World Conference on Drugs in Sport.
Member of Organizing Committee
Moscow, USSR. September, 1989.

Department of Defense.
Two day seminar on Anabolic steroids.
The Pentagon, November 16-17, 1990.

**SEMINARS & SYMPOSIA ORGANIZED AND PRESENTED, since 1989**

United States Olympic Committee (USOC).
Chair UCLA CME Course on Drugs in Sport for Physicians.
Colorado Springs, Colorado. May 18-20, 1991.

Third Permanent World Conference on Drugs in Sport.
Member of Organizing Committee and Speaker
Bergen, Norway. September 20-26, 1991.

United States Olympic Committee.
Co-Chair UCLA CME course on Drugs, Athletes, and Testing.
Colorado Springs, CO. March 10-12, 1993.

Fourth Permanent World Conference on Drugs in Sport.
Member of Organizing Committee and Speaker
London, England. September 4-8, 1991.

United States Olympic Committee.
Co-Chair CME course on Drugs, Athletes, and Testing.
Colorado Springs, CO. June 3-5, 1994.

United States Anti-Doping Agency.
Co-Sponsor Conference on Carbon Isotope Ratio Techniques
Los Angeles, CA. August, 2003.

**PRINCIPAL CONSULTANT TO MAJOR SPORT EVENTS:**

Summer Olympic Games of Los Angeles, 1984
Director of Laboratory

World University Games.
Buffalo, NY. 1991-1993.

Goodwill Games, Member of Medical Commission
Seattle, Washington 1990.
Director of Laboratory

Summer Olympic Games of Seoul, 1988
Pan American Games, Member of Medical Commission
Havana, Cuba July 1991.

Winter Olympic Games of Albertville, 1992.
Member of Medical Commission
Albertville, France. 1991-1992.

Summer Olympic Games of Barcelona, 1992.
Member of Medical Commission
Barcelona, Spain. 1990-1992.

Americas Cup Race, 1992, San Diego, CA. 1992.

Central American and Caribbean Games
Member of Medical Commission
Director of Laboratory/Transfer of Accreditation
San Juan, Puerto Rico 1992-1993.

Winter Olympic Games of Lillehammer, 1994
Member of Medical Commission
Lillehammer, Norway. 1991-1992.

World Cup Soccer, FIFA, Director of Laboratory
United States, 1991-1994.

Goodwill Games, St. Petersberg, Russia 1994.

Olympic Games of Atlanta, 1996
Atlanta, Georgia. 1992-1996.
Director of Steroid Testing Laboratory

**PRINCIPAL CONSULTANT TO MAJOR SPORT EVENTS (continued):**

Winter Olympic Games of Nagano, 1998
Member of IOC Medical Commission
Nagano, Japan

Summer Olympic Games of Sydney, 2000
Member of IOC Medical Commission
Sydney, Australia

Winter Olympic Games of Salt Lake, 2002
Member of IOC Medical Commission
Director of Laboratory

Summer Olympic Games of Athens, 2004
Member of IOC Medical Commission

Winter Olympic Games of Torino, 2006
Member of IOC Medical Commission

**SPORT CONSULTATIONS ON LEGAL TESTING MATTERS, since 1990**

National Football League, various, 1989-

USOC and National Governing Sport Bodies: 1984-2001.

United States Anti-doping Agency (USADA), several per year, 2001-

Chambers vs. UK Athletics: Tetrahydrogestrinone, 2004.

International Olympic Committee, Court of Arbitration for Sport

Arbitral Award: CAS 2002/A/370 Lazutina v/ IOC
Arbitral Award: CAS 2002/A/374 Muehlegg v/ IOC
Arbitral Award: CAS 2002/A/376 Baxter v/ IOC
Arbitral Award: CAS 2002/A/389-393 (Austrian Ski Team) v/ IOC

**PUBLICATIONS:**

1. Powell DW, Plotkin GR, Maenza RM, Solberg LI, Catlin DH, Formal SB. Experimental diarrhea I. Intestinal water and electrolyte transport in rat salmonella enterocolitis. Gastroenterology 1971;60:1053-1064.

2. Powell DW, Plotkin GR, Solberg LI, Catlin DH, Maenza RM, Formal SB. Experimental diarrhea II. Glucose-stimulated sodium and water transport in rat salmonella enterocolitis. Gastroenterology 1971;60:1065-1075.

3. Powell DW, Solberg LI, Plotkin GR, Catlin DH, Maenza RM, Formal SB. Experimental diarrhea III. Bicarbonate transport in rat salmonella enterocolitis. Gastroenterology 1971; 60:1076-1086.

4. Adler FL, Liu CT, Catlin DH. A rapid serological screening test for morphine. Abstracts of Federation Proceedings, 1972.

5. Catlin DH, Cleeland R, Craves F, Grunberg E. A rapid and sensitive radioimmunoassay for detection of morphine in urine and serum. Abstracts of the American Public Health Association Meeting, 1972.

6. Adler FL, Liu CT, Catlin DH. Immunological studies on heroin addiction I. Methodology and application of a hemagglutin-ation inhibition test for detection of morphine. Clin Immununol Immunopathol 1972;1:53-68.

7. Catlin DH, Cleeland R, Grunberg E. A sensitive, rapid radioimmunoassay for morphine and immunologically related substances in urine and serum. Clin Chem 1973;19:216-220.

8. Catlin DH, Adler FL, Liu CT. Immunological studies on heroin addiction II. Applications of a sensitive hemagglutination-inhibition test for detecting morphine to diagnostic problems in chronic heroin addiction. Clin Immunol Immunopathol 1973;1:446-455.

9. Catlin DH. Urine testing: A comparison of five current methods for detecting morphine. Am J Clin Pathol 1973; 60:719-728.

10. Catlin DH. A Guide to Urine Testing for Drugs of Abuse. Washington, DC: U.S. Government Printing Office, 1973.

11. Catlin DH. Evaluation and clinical application of the immunoassays for morphine. In: Sunshine I, Mule SJ, Braude MC, eds. Immunoasssays for Drugs Subject to Abuse. Cleveland: CRC Press, 1974.

**PUBLICATIONS (Continued):**

12. Gorodetsky CW, Angel CR, Beach DJ, Catlin DH, Yeh S. Validity of screening methods for drugs of abuse in biological fluids. I. Heroin in urine. Clin Pharmacol Ther 1974; 15:461-472.

13. Catlin DH, Jenden DJ. Estimation of morphine in biological samples by immunoextraction and GC/MS. Abstracts International Congress of Pharmacology, 6th Proceeding, Helsinki, Finland, 1975.

14. Catlin DH, Schaeffer JC, Fischer JF. Production and characterization of antibodies to meperidine. Res Commun Chem Path Pharmacol 1975;11:245-256.

15. Clausen JL, Hill RN, Liewen MB, Catlin DH. Arterial and venous lidocaine levels during anesthesia of upper and lower airways. Clin Res 1976; 24:159A.

16. Catlin DH, Schaeffer JC, Liewen MB. 2-Diazomorphine directed anti-serum: Determination of morphine in brain after naloxone challenge in morphine pellet implantation in mice. Life Sci 1977;20:123-132.

17. Catlin DH, Liewen MB, Schaeffer JC. Brain levels of morphine in mice following removal of a morphine pellet and naloxone challenge: No evidence for displacement. Life Sci 1977; 20:133-139.

18. Catlin DH. Pharmacokinetics of morphine by radioimmunoassay: The influence of immunochemical factors. J Pharmacol Exp Ther 1977;200:224-235.

19. Dum J, Meyer G, Hollt V, Herz A, Catlin DH. Inability of naloxone to change morphine brain levels in tolerant mice. Eur J Pharmacol 1977;46:165-170.

20. Catlin DH, Hui KK, Loh HH, Li CH. Pharmacologic activity of beta-endorphin in man. Commun Psychopharmacol 1977;1:493-500.

21. Catlin DH, Hui KK, Loh HH, Li CH. Beta-endorphin: Subjective and objective effects during acute narcotic abstinence in man. Adv Biochem Psychopharmacol 1978;18:341-350.

22. Catlin DH, George R, Li CH. Beta-endorphin: Pharmacologic and behavioral activity in cats after low intravenous doses. Life Sci 1978;23:2147-2154.

23. Gorelick DA, Catlin DH, George R, Li CH. Beta-endorphin is behaviorally active in rats after chronic intravenous administration. Pharmacol Biochem Behav 1978;9:385-386.

24. Catlin DH, Hui KK, Loh HH, Li CH. Beta-endorphin: Initial clinical studies. In: Usdin E, Kline NS, Bunney WE Jr, eds. Endorphins in Mental Health Research. New York: MacMillan Press, 1979, pp. 535-544.

**PUBLICATIONS (Continued):**

25. Hui KK, Catlin DH, Conolly ME, Li CH. Human beta-endorphin, cyclic AMP and the human lymphocyte beta-adreno-receptor. World Conference on Clinical Pharmacology and Therapeutics, London, August 3-9, 1980. (Abstract)

26. Catlin DH, Gorelick DA, Gerner RH, Hui KK, Li CH. Clinical studies with human beta-endorphin. In: Beers RF, Bassett EG, eds. Polypeptide Hormones, No. 12. New York: Raven Press, 1980:337-346.

27. Catlin DH, Gorelick DA, Gerner RH, Hui KK, Li CH. Clinical effects of beta-endorphin infusions. Adv Biochem Psychopharmacol 1980;22:465-472.

28. Catlin DH, Poland RE, Gorelick DA, Gerner RH, Hui KK, Rubin RT, Li CH. Intravenous infusion of beta-endorphin increases serum prolactin, but not growth hormone or cortisol in depressed subjects and withdrawing methadone addicts. J Clin Endocrinol Metab 1980; 50:1021-1025.

29. Bajorek JC, Catlin DH, Lomax P. Anticonvulsant activity of beta-endorphin in the seizure sensitive mongolian gerbil. Society for Neurosciences, Cincinnati, Ohio. November, 1980. (Abstract)

30. Gerner RH, Catlin DH, Gorelick DA, Hui KK, Li CH. Beta-endorphin: Intravenous infusion causes behavioral change in psychiatric in-patients. Arch Gen Psychiatry 1980;37:642-647.

31. Catlin DH, Smith RA, Samuels AI. $^{14}$C-Ribavirin: Distribution and pharmacokinetic studies in rats, baboons, and man. In: Smith RA, Kirkpatrick W, eds. Ribavirin: A Broad Spectrum Antiviral Agent. New York: Academic Press, 1980, pp. 83-98.

32. Robinson JS, Catlin DH, Barrett CT. Withdrawal from methadone by breast feeding. In: Stern L, ed. Intensive Care in the Newborn. New York: Masson Publishers, 1980, pp. 213-218.

33. Gerner RH, Gorelick DA, Catlin DH, Li CH. Behavioral effects of beta-endorphin in depression and schizophrenia. In: Shah NS, Donald AG, eds. Endorphins and Opiate Antagonists in Psychiatric Research: Clinical Implications. New York: Plenum Press, 1980.

34. Catlin DH, Gerner RH, Gorelick DA. Beta-endorphin: Behavioral effects of single and multiple infusions - Measurement of CSF levels. Third World Congress of Biological Psychiatry, Stockholm, Sweden, 1980; S56 (Abstract).

35. Gorelick DA, Catlin DH, Gerner RH. Beta-endorphin studies in psychiatric patients. In: Emrich HM, ed. Modern Problems in Pharmacopsychiatry, Vol 17. Basel, Switzerland: S. Karger, 1981:236-245.

**PUBLICATIONS (Continued):**

36. Catlin DH, Gorelick DA, Gerner RH. Studies of beta-endorphin in patients with pain and drug addiction. In: Li CH, ed. Hormonal Proteins and Peptides, Vol 10. New York: Academic Press, 1981:311-338.

37. Bajorek JG, Lee RJ, Catlin DH, Lomax R. Effects of beta-endorphin on experimentally induced seizures in mice. Proc West Pharmacol Soc 1981;24:315-317.

38. Catlin DH, Gorelick DA, Gerner DH. Clinical pharmacology of beta-endorphin in depression and schizophrenia. In: Verebey K, ed. Annals of the New York Academy of Sciences. New York: Academy of Sciences, 1982:434-447.

39. Gerner RH, Gorelick DA, Catlin DH, Sharp B. Endorphins: CSF levels and multidose studies in psychiatric subjects. In: Perris C, Struwe G, Jansson B, eds. Biological Psychiatry 1981. Elsevier: North Holland Biomedical Press, 1981:386-389.

40. Gerner RH, Sharp B, Catlin DH. Peripherally administered beta-endorphin increases cerebrospinal fluid endorphin immunoreactivity. J Clin Endocrinol Metab 1982;55:358-360.

41. Catlin DH. Pharmacokinetics. In: Bevan JA, Thompson JH, eds. Essentials of Pharmacology, 3rd ed. New York: Harper and Row, 1983:46-61.

42. Catlin DH. Opioids: Agonists, antagonists, and mixed antagonist-agonists. In: Bevan JA, Thompson JH, eds. Essentials of Pharmacology, 3rd ed. New York: Harper and Row, 1983:318-330.

43. Strauss RH, Wright JE, Finerman GAM, Catlin DH. Side effects of anabolic steroids in weight-trained men. Physician and Sports Medicine 1983; 11:87-96.

44. Batzdorf U, Catlin DH. Pain syndromes in malignant disease. In: Haskell CM, ed. Cancer Treatment, 2nd ed. New York: W.B. Saunders, 1985:928-940.

45. Wright J, Bahrke M, Strauss R, Catlin DH. Psychological states, behavioral changes and somatic perception accompanying anabolic steroid usage. American College of Sports Medicine, 1985. (Abstract).

46. Strauss RH, Catlin DH, Morgan JP, Murphy RJ, Murray TH, Puffer JC, Voy RO. Drug testing in sports: A round table. Physician and Sports Medicine 1985;13:69-82.

47. Catlin DH. Detection of drug use by athletes. In: Strauss R, ed. Drugs and Performance in Sports. New York: W.B. Saunders, 1987:103-120.

**PUBLICATIONS (Continued):**

48. Catlin DH, Hatton CK. Clinical pharmacology of androgenic anabolic steroids (AAS) in sport. Acta Pharmacol et Toxicol 1986 (Suppl V)(Abstract 16).

49. Catlin DH, Hatton CK. Identification of boldenone, a veterinarian androgenic anabolic steroid, in the urine of bodybuilders. Acta Pharmacol et Toxicol 1986 (Suppl V) (Abstract 349).

50. Kammerer RC, Merdink J, Jagels M, Hui K, Catlin DH. Fluoxymesterone metabolism in man. 192nd American Chemical Society Meeting, Anaheim, California, September, 1986. (Abstract).

51. Catlin DH. Adverse effects of blood transfusions. Olympic Review 1987; 231:37-41.

52. Catlin DH, Kammerer RC, Hatton CK, Sekera MH, Merdink JM. Analytical chemistry at the Games of the XXIIIrd Olympiad in Los Angeles, 1984. Clin Chem 1987;33:319-327.

53. Hatton CK, Catlin DH. Detection of androgenic anabolic steroids in urine. Clinics in Laboratory Medicine 1987;7:655-668.

54. Elliot DL, Goldberg L, Kuehl KS, Catlin DH. Characteristics of anabolic-androgenic steroid-free competitive male and female bodybuilders. Physician and Sports Med 1987; 15:169-179.

55. Hatton CK, Catlin DH. Urinary steroid profiles of athletes. 35th American Society Mass Spectrometry, Denver Colorado, May 24-29, 1987. (Abstract).

56. Barriere SL, Orlando PL, Catlin DH. Pharmacokinetic disposition and pharmacodynamic effects of IV Ciprofloxacin (C) and Azlocillin (A) given alone and in combination to healthy subjects. Abstracts of the 1988 ICAAC, 1988:245 (Abstract 768).

57. Catlin DH and Hatton CK. Introduction to and use of frequency distributions to distinguish between urinary 19-norandrosterone arising from the administration of norethisterone or that of 19-norestosterone. First International Symposium on Drugs in Competitive Athletics, Brioni, May 29-June 2, 1988. (Abstract).

58. Catlin DH. Drugs in competitive athletics. First International Symposium on Drugs in Competitive Athletics, Brioni, May 29-June 2, l988. (Abstract).

59. Brower KJ, Eliopulos GA, Blow FC, Catlin DH, Beresford TP. Evidence for physical and psychological dependence on anabolic-androgenic steroids in eight weight lifters. Am J Psychiat 1990;147:510-512.

60. Batzdorf U, Catlin DH. Pain syndromes in malignant disease. In: Haskell CM, ed. Cancer Treatments, 3rd ed. New York: W.B. Saunders, 1990:874-883.

**PUBLICATIONS (Continued):**

61. Barriere SL, Catlin DH, Orlando PL, Hindler JA, Noe A, Frost RW. Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. Antimicrobial Agents and Chemotherapy 1990;34:823-826.

62. Edmond JE, Korsak RA, Morrow JW, Torok-Both G, Catlin DH. The origin of cholesterol in brain of the developing rat. Fed Am Soc Exp Biol 1990. (Abstract).

63. Catlin DH, Hatton CK. Use and abuse of anabolic and other drugs for athletic enhancement. Adv Int Med 1991;36:399-424.

64. Catlin DH. Pharmacokinetics and interpretation of test results. Fresenius J Anal Chem 1990; 337:50.

65. Bahrke MS, Wright JE, O'Connor JS, Strauss RH, Catlin DH. Selected psychological characteristics of anabolic-androgenic steroid users (Letter to the Editor). N Engl J Med 1990;323:834-835.

66. Kammerer RC, Merdink J, Jagels M, Catlin DH, Hui, KK. Testing for fluoxymesterone (Halotestin) administration to man: Identification of urinary metabolites by gas chromatography-mass spectrometry. J Steroid Biochem 1990;36:659-666.

67. Brower KJ, Catlin DH, Blow FC, Eliopulos GA, Beresford TP. Clinical assessment and urine testing for anabolic androgenic steroid abuse and dependence. Am J Drug Alcohol Abuse 1991;17:161-172.

68. Catlin DH, Starcevic B. HPLC method for the assay of creatinine in urine. J Liquid Chromatog 1991;14:2399-2408.

69. Hatton CK, Catlin DH, Straus PW, Starcevic SH. Urinary steroid profiles: A longitudinal study. 38th ASMS Conference on Mass Spectrometry and Allied Topics, Tucson, Arizona, June 3-8, 1990. (Extended Abstract)

70. Edmond J, Korsak RA, Morrow JW, Torok-Both G, Catlin DH. Dietary cholesterol and the origin of cholesterol in the brain of developing rats. J Nutr 1991;121:1323-1330.

71. Thompson PD, Sadaniantz A, Cullinane MS, Bodziony KS, Catlin DH, Torok-Both GT, Douglas PS. Left ventricular function is not impaired in weightlifters using anabolic steroids. J Am Coll Cardiol 1992;19:278-282.

72. Bahrke MS, Wright JE, Strauss RH, Catlin DH. Psychological moods and subjectively perceived behavioral and somatic changes accompanying anabolic-androgenic steroid usage. Am J Sports Med 1992;20:717-724.

**PUBLICATIONS (Continued):**

73. Catlin DH. Anabolic steroids monitoring - Clinical interpretation and analytical challenges. 1992 Pittsburgh Conference and Exposition, New Orleans, March 9-12, 1992. (Abstract 026).

74. Catlin D, Cowan D, Donike M, Fraisse D, Oftebro H, Rendic S. Testing urine for drugs (Position paper of the International Federation of Clinical Chemistry). Clinica Chimica Acta 1992;207:S13-S26.

74a. Catlin D, Cowan D, Donike M, Fraisse D, Oftebro H, Rendic S. Testing urine for drugs (Position paper of the International Federation of Clinical Chemistry, reprinted). J Auto Chem 1992;14:85-92.

74b. Catlin D, Cowan D, Donike M, Fraisse D, Oftebro H, Rendic S. Testing urine for drugs (Position paper of the International Federation of Clinical Chemistry, reprinted). Ann Biol Clin 1992;50:359-366.

74c. Catlin D, Cowan D, Donike M, Fraisse D, Oftebro H, Rendic S. Testing urine for drugs (Position paper of the International Federation of Clinical Chemistry, reprinted). Europ J Clin Chem Clin Biochem. 1993;41-49.

74d. Catlin D, Cowan D, Donike M, Fraisse D, Oftebro H, Rendic S. Testing urine for drugs (Position paper of the International Federation of Clinical Chemistry, reprinted). J Internat Fed Clin Chem. 1993

75. Catlin DH. Analytical consideration in doping control in Olympic sports medicine - Challenges for the 90's. Federation of Analytical Chemistry and Spectroscopy Studies' Eighteenth Annual Meeting, Anaheim, California, October 6-11, 1991. (Abstract 20).

76. Catlin DH, Cowan DA. Detecting testosterone administration. Clin Chem 1992;38:1685-1686. (Editorial)

77. Thompson PD, Zmuda JM, Catlin DH. Use of anabolic steroids among adolescents. N Engl J Med 1993;329:888-889. (Letter to the editor)

78. Catlin DH, Wright J, Pope H Jr, Liggett M. Assessing the threat of anabolic steroids. Discussion. Ed: Strauss RH. Phys and Sportsmed 1993;21:37-44.

78a. Catlin DH, Wright J, Pope H Jr, Liggett M. Assessing the threat of anabolic steroids. Discussion. Ed: Strauss RH. Reprinted in Muscle and Fitness. April, 1994. (Reprint)

79. Zmuda JM, Fahrenbach MC, Younkin BT, Bausserman LL, Terry RB, Catlin DH, Thompson PD. The effect of testosterone aromatization on high-density lipoprotein cholesterol and postheparin lipolytic activity. J Clin Endocrinol Metab 1993;42:446-450.

**PUBLICATIONS (Continued):**

80. Catlin DH, Sekera M, Adelman DC. Exfoliative dermatitis associated with ingestion of an herbal product. Western J Med 1993;159:491-493.

81. Catlin DH, Salehian B, Boghosian T, Swerdloff RS, Wang C. Changes in urinary testosterone and epitestosterone after sublingual testosterone cyclodextrin administration. Clinical Research, 1993; vol 42. (Abstract).

82. Catlin DH. Testing succeeds in keeping sports clean. Editorial in USA Today. October 12, 1994 p8C.

83. Catlin DH. Anabolic steroids. In DeGroot LJ, ed. Endocrinology, 3rd ed. Orlando, Florida: W.B. Saunders Co. 1995:2362-2376.

84. Catlin DH. Ratio of testosterone to epitestosterone in urine: Clinical and analytical considerations in the context of doping control. In: Cowan DA, Kicman AT, eds. Control of Doping with Anabolic Agents: Proceedings of the Scientific Meeting of the 4th Permanent World Conference on Antidoping in Sport, London. Caligraving Limited, Thetford, Norfolk, Great Britain. 1994:2-8.

85. Catlin DH. Androgen abuse by athletes. In: Bhasin S, Gabelnick HL, Spieler JM, Swerdloff RS, Wang C. Kelly C, eds. International Androgen Workshop (2nd): Pharmacology, Biology, and Clinical Applications of Androgens: current status and future prospects. Wiley-Liss, Inc., New York, 1995:289-300.

86. Aguilera R, Becchi M, Casabianca H, Hatton CK, Catlin DH, Starcevic B, Pope HG. Improved method of detection of testosterone abuse by gas chromatography/ combustion/isotope ratio mass spectrometry analysis of urinary steroids. J Mass Spectrometry 1996;31:169-176.

87. Catlin DH, Cowan DA, de la Torre R, Donike M, Fraisse D, Oftebro H, Hatton CK, Starcevic B, de la Torre X, Norli H, Geyer H, Walker CJ. Urinary testosterone (T) to epitestosterone (E) ratios by GC/MS. I. Initial comparison of uncorrected T/E in six international laboratories. J Mass Spectrometry 1996;31:397-402.

88. Catlin DH, Murray TH. Performance Enhancing Drugs, Fair Competition, and Olympic Sport. JAMA 1996;276:231-237.

89. Catlin DH, Murray TH. Response to: Performance Enhancing Drugs, Fair Competition, and Olympic Sport. JAMA 1996;276:1471. (Letter to Editor)

90. Catlin DH, Hatton CK, Starcevic S. Issues in detecting xenobiotic anabolic steroids and testosterone by analysis of athletes' urine. Clin Chem 1997;43:1280-1288.

**PUBLICATIONS (Continued):**

91. Olesen H, Cowan D, Klempel K, Bruunshuus I, Hill G. International Federation of Clinical Chemistry: Committee on Laboratory Assessment on Drugs of Abuse (DH Catlin, Chairman) and Committee on Quantities and Units, and International Union of Pure and Applied Chemistry. Properties and units in drugs of abuse. (Committee work product, Chairperson of committee, 1997)

92. Catlin, DH. Effects and complications of anabolic androgenic steroids. In: Karch, SB, ed. Handbook on Drug Abuse. CRC Press LLC, 1998:653-662..

93. Starcevic B, Catlin DH, Di Stefano E, Luo W. Quantitative determination of anabolic steroid conjugates in human urine by LC-MS-MS. Proceedings of the 46th ASMS Conference on Mass Spectrometry and Allied Topics, Orlando, Florida, May 31-June 4, 1998. (Extended abstract).

94. Starcevic B, Di Stefano E, Catlin DH,, Luo W, Tabuchi R, Ghoborah H. Assay of Oxandrolone in Plasma and Urine. Proceedings of the 45th ASMS Conference on Mass Spectrometry and Allied Topics, Palm Springs, California, June 1-5, 1997. (Extended abstract).

95. Vihil DV, Puffer JC, Catlin, DH, Johnson TW, Jung ME, Starcevic B. Thermoprotective effect of bromantan administered to rats before aerobic exercise. Am College of Sports Medicine, June, 1998. (Abstract)

96. Lee EK, Starcevic S, Catlin DH. Effects of dietary supplements, 19-norandrostenedione, androstenediol and androstenedione on the profile of urine steroids. Western Society of Clinical Investigation. Carmel, Ca. January, 1999. (Abstract)

97. Catlin DH. Androgen abuse in sport: International and national anti-androgen programs. In: Wang C, Swerdloff R, eds. Male Reproduction Function. Kluwer Academic Publishers, 1999.

98. Longman J. Getting the chemical edge. [Catlin DH, Graphic text/illustration] New York Times, December 26, 1998. p A1 and p B6-B7.

99. Aguilera R, Catlin DH, Becchi M, Phillips A, Wang C, Swerdloff RS, Pope HG, Hatton CK. Screening urine for exogenous testosterone by isotope ratio mass spectrometric analysis of one pregnanediol and two androstanediols. J Chromatog B 1999;727:95-105.

100. Catlin DH. Doping. International Olympic Committee; 1999:1-40.

101. Sheffield-Moore M, Ferrando AA, Urban RJ, Wolf SE, Jiang J, Catlin DH, Herndon DH, Wolfe RR. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. Endocrine Society, 1999 (Abstract)

**PUBLICATIONS (Continued):**

102. Wang C, Catlin DH, Ambler C, Berman N, Lucas G, Leung A, Lee P, Starcevic B, Schramm KM, Swerdloff RS. Dietary fat modulation of androgen metabolism in normal men. Endocrine Society, 1999 (Abstract)

103. Leder BZ, Longcope C, Catlin DH, Ahrens B, Schoenfeld DA, Finkelstein JS. Oral androstenedione administration increases serum testosterone concentrations in young men. Endocrine Society, 1999 (Abstract)

104. Strawford A, Barbieri T, Van Loan M, Park E, Catlin DH Barton N, Neese R, Crristiansen M, King J, Hellerstein M. Effects of resistance exercise combined with supraphysiologic androgen therapy, including an anabolic steroid, oxandrolone, on lean tissue accrual and muscle strength in eugonadal men with HIV-related weight loss. A randomized, placebo-controlled trial. JAMA 1999;281:1282-1290.

105. Moore MS, Urban RJ, Wolf SE, Jiang J, Catlin DH, Herndon DN, Wolfe RR, Ferrando AA. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab 1999;84:2705-2711.

106. Shipley A. With drug tests, answers are few. [Catlin, DH. Graphics, photos, text] Washington Post. September 22, 1999 p D1, D6-7, and September 23, 1999 p D1, D10-11.

107. Leder BZ, Longcope C, Catlin DH, Ahrens B, Schoenfeld DA, Finkelstein JS. Oral androstenedione administration increases serum testosterone concentrations in young men. JAMA 2000;283:779-782.

108. Starcevic B, Di Stefano E, Catlin DH. LC/MS/MS screening for beta-blockers and beta-2 agonists in urine with automated sample preparation. Proceedings of the 45th ASMS Conference on Mass Spectrometry and Allied Topics, Anaheim, California, June, 2000. (Extended abstract)

109. Aguilera R, Chapman TE, Catlin DH. Fast screening method for the detection of exogenous anabolic steroids in urine by gas chromatography / combustion / isotope ratio mass spectrometry. Proceedings of the 45th ASMS Conference on Mass Spectrometry and Allied Topics, Anaheim, California, June, 2000. (Extended abstract 1535)

110. Catlin DH. Use and abuse of anabolic steroids. In DeGroot LJ, ed. Endocrinology, 4th ed. Orlando, Florida: W.B. Saunders Co. 2000:2243-2256.

111. Aguilera R, Chapman TE, Catlin DH. A rapid screening assay for measuring urinary androsterone and etiocholanolone $\delta^{13}(^{0}/_{00})$ values by gas chromatography/combustion /isotope ratio mass spectrometry. Rapid Comm Mass Spec 2000;14:2294-2299.

**PUBLICATIONS (Continued):**

112. Catlin DH, Leder BZ, Ahrens B, Starcevic B, Hatton CK, Green GA, Finkelstein JS. Trace contamination of over-the-counter androstenedione and positive urine test results for a nandrolone metabolite. JAMA 2000;284:2618-2621.

113. Aguilera R, Chapman TE, Catlin DH. Performance characteristics of a carbon isotope ratio method for detecting doping with testosterone based on urine diols: controls and athletes with elevated testosterone/epitestosterone ratios. Clin Chem 2001;47:292-300.

114. Catlin, DH, Jackson R.. Doping Control. In: Jackson R, ed. IOC Sport Medicine Manual, 2000 Hurford Enterprises Ltd., Calgary, Canada. 2000:332-343.

115. Catlin, DH. Hatch does not have all the facts. Salt Lake City Tribune, December 29, 2000. (Editorial)

116. Leder BZ, Catlin DH, Longcope C, Ahrens B, Schoenfeld DA, Finkelstein JS. Metabolism of orally administered androstenedione in young men. J Clin Endocrinol Metab 2001; 86:3654-3658.

117. Breidbach A, Catlin DH. RSR13, A potential athletic performance enhancement agent: detection in urine by GC-MS. Rapid Commun Mass Spectrom 2001;15:2379-82.

118. Green GA, Starcevic B, and Catlin DH. Analysis of over-the-counter steroid supplements. Clin J Sports Med 2001;11:254-259.

119. Catlin, DH, Leder BZ, Ahrens BD, Hatton CK, Finkelstein JS. Epitestosterone: precursor, metabolites, and effect of androstenedione administration. Steroids 2002;67:559-564.

120. Aguilera R, Hatton CK, Catlin DH. Detection of doping with epitestosterone by isotope ratio mass spectrometry. Clin Chem 2002;48:629-636.

121. Catlin DH, Ahrens BD, Kucherova Y. Detection of norbolethone, an anabolic steroid never marketed, in athletes' urines. Rapid Commun Mass Spectrom 2002;16:1273-1275.

122. Catlin DH, Breidbach A, Elliott S, Glaspy J. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem 2002;48:2057-2059.

123. Leder BZ, Leblanc KM, Longcope C, Lee H, Catlin DH, Finkelstein JS. Effects of oral androstenedione administration on serum testosterone and estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2002;87:5449-5454.

124. Starcevic B, DiStefano E, Wang C, Catlin DH. Liquid chromatographic-tandem mass spectrometric assay for human testosterone and deuterated testosterone. Journal of Chromatography B 2003;792:197-204.

**PUBLICATIONS (Continued):**

125. Breidbach A, Catlin DH, Green GA, Tregub I, Truong H. Gorzek J. Detection of rHuEPO in urine by isoelectric focusing. Clin Chem 2003;49:901-907.

126. Catlin DH, Hatton CK, Lasne F. Abuse of Recombinant Erythropoietins by Athletes. In: Molineux G, Foote MA, Elliott S, eds. Erythropoietins and erythropoiesis: Molecular, Cellular, Preclinical, and Clinical Biology. Birkhäuser Verlag, 2003:205-227.

127. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: Comparison of current laboratory methods *versus* liquid chromatography-tandem mass spectrometry. J Clin Endocrin Metab 2004;89:534-543.

128. Wang C, Catlin DH, Starcevic B, Leung A, DiStefano E, Lucas G, Hull L, Swerdloff RS. Testosterone metabolic clearance and production rates determined by stable isotope dilution/tandem mass spectrometry in normal men: Influence of ethnicity and age. J Clin Endocrin Metab 2004;89:2936-2941.

129. Jasuja R, Catlin DH, Miller A, Chang Y-C, Singh R, Starcevic B, Artaza J, Ramaraj P, Bhasin S. Tetrahydrogestrinone (THG) binds to androgen receptor (AR) and activates AR-mediated signaling pathway. Endocrine Society, 2004 (Abstract)

130. Catlin DH, Sekera, MH, Ahrens BD, Starcevic B, Chang Y-C, Hatton CK. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Commun Mass Spectrom 2004;18:1245-1249.

131. Sekera MH, Ahrens BD, Chang Y-C, Starcevic B, Georgakopoulos C, Catlin DH. Another designer steroid: discovery, synthesis, and detection of 'madol' in urine. Rapid Commun Mass Spectrom 2005;19:781-784.

132. Wang C, Catlin DH, Starcevic B, Heber D, Ambler C, Berman N, Lucas G, Leung A, Schramm, Lee PWN, Hull L, Swerdloff RS. Low fat high fiber diet decreased serum and urine androgens in men. J Clin Endocrin Metab 2005;90:3550-3559.

133. Chang Y-C, Starcevic B, Ahrens BD, Strouse JM, Catlin DH. Identification of a urinary metabolite of the designer steroid tetrahydrogestrinone. 53rd Amer Soc Mass Spec Conference, San Antonio, 2005 (lognumber 1980).

134. Jasuja R, Catlin DH, Miller A, Chang Y-C, Herbst KL, Starcevic B, Artaza JN, Singh R, Datta D, Sarkissian A, Chandsawangbhuwana C, Baker M, Bhasin S. Tetrahydro-gestrinone is an androgenic steroid that stimulates androgen receptor-mediated, myogenic differentiation in C3H10T1/2 multipotent mesenchymal cells and promotes muscle accretion in orchidectomized male rats. Endocrinology. 2005;146:4472-4478.

**PUBLICATIONS (Continued):**

135. Catlin DH, Chang YC, Starcevic B, Hatton CK. LC-MS measurement of anabolic steroids. In Chromatographic methods in clinical chemistry and toxicology. Eds Bertholf RL and Winecker RE. Chichester, U.K.: John Wiley & Sons. (In press, 2006)

136. Catlin DH, Starcevic B, Chang YC, Hatton CK. Sports doping analysis using LC-MS. Chapter 8-8 in Encyclopedia of Mass Spectrometry. Eds. Gross ML and Caprioli R. Vol.8, Clinical, toxicological and forensic applications. Oxford: Elsevier. (In press, 2006).

137. Catlin DH. Use and abuse of anabolic steroids. In DeGroot LJ, and Jameson JL eds. Endocrinology, 5th ed. Orlando, Florida: W.B. Saunders Co. 2006:2243-2256.

138. Catlin DH, Green G, Sekera MH, Scott P, Starcevic B. False positive EPO test concerns unfounded. Blood 2006;108:1778. (Letter to the editor)

139. Catlin DH, Green GG, Hatton CK. Drugs in Sport. In The Olympic book of Medicine in Sport. Ed. Schwellnus M. Blackwell Publishing Ltd. (In press, 2006)

140. Jeong, J-Y, Changmin C, Davis KL, Breidbach A, Catlin DH, Sytkowski, AJ. Erythropoietin Fusion Proteins Comprised of Identical Head-to-Tail Repeats with Enhanced Biological Activity. (Abstract, 2006)

141. Catlin, DH, Starcevic, SH, Ahrens BD, Kucherova Y, Sekera MH, Sergeeva T, Starcevic B. Detection of 19-Norandrosta-4,9-diene-3,17-dione and Dehydronandrolone in Athletes' Urine. (Submitted for publication)

## NEWSPAPER ARTICLES BASED ON ANALYTICAL WORK OF CATLIN, DH AND OTHERS AT THE UCLA OLYMPIC ANALYTICAL LABORATORY

1. Shipley A. Chemists Stay a Step Ahead of Drug Testers. Washington Post. October 18, 2005;p E01

2. Shipley A. Chemist's New Product Contains Hidden Substance. Washington Post. May 8, 2006, p E01

## FILM

1. Doping: The battle for the soul of Sport. Hilton Cordell Productions for Discovery Times Channel in Association with the Canadian Broadcasting corporation and the Australian Broadcasting Corporation, 2004. (http://www.hiltoncordell.com/)